THE RELATIONSHIP BETWEEN PLASMA SOLUBLE TNF-LIKE WEAK INDUCER OF APOPTOSIS LEVEL AND INFLAMMATORY MARKERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Tarih
2014Yazar
Yamak, M.
Demir, S.
Gursu, M.
Ozturk, Savaş
Sumnu, A.
Cebeci, E.
Ozkan, O.
Karadag, S.
Sakci, E.
Kural, A.
Koldas, M.
Sar, F.
Üst veri
Tüm öğe kaydını gösterÖzet
Soluble TNF-like weak inducer of apoptosis (sTWEAK) is a member of the TNF super family with many biological activities. There is a limited number of studies on the role of sTWEAK in chronic kidney disease. We aimed in this study to examine the relation of sTWEAK with albuminuria and inflammatory markers in patients with type 2 diabetes mellitus (DM). One hundred and eighteen diabetic patients with varying levels of albuminuria were included. Group 1 comprised patients with albuminuria less than 30 mg/day, while Group 2 and Group 3 were composed of patients with albuminuria between 30-300 mg/day or more than 300 mg/day, respectively. Groups were compared for sTWEAK levels besides demographic, clinical and biochemical data. There was no difference between groups regarding sTWEAK and TNF-alpha levels. IL-1 levels in Group 1 were higher than in Group 3. hsCRP levels were significantly higher in Group 3 compared to other groups. Use of a renin angiotensin system blocker did not have any effect on sTWEAK, TNF-a and hsCRP levels, while IL-1 level was significantly lower in patients using a renin angiotensin blocker. A statistically significant positive correlation was detected between sTWEAK and IL-1 levels (r=0.245; p=0.008). The groups were found to be similar regarding sTWEAK and TNF-alpha level. This finding may be interpreted as there being no effect of proteinuria on sTWEAK levels. But the close correlation between proteinuria and IL-1, and between IL-1 and sTWEAK may be a clue for an indirect relationship. Lack of difference between groups regarding sTWEAK levels may be due to involvement of patients with GFR more than 60 ml/minute only.
Koleksiyonlar
- Makale [92796]